From: Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
Dose level [mg/mq/die]
No cycles administered [1 cycle = 21 days]
No. of patients
No. cycles per patient median [range]
1500
21
3
5 [2–14]
1750
33
10 [4–19]
2000
24
3 [2–19]
2250
8 [5–11]
2500
28
6
7 [2–10]
2750
49
9
5 [2–12]